Asarinin inhibits immunological rejection via the Toll-like receptor-myeloid differentiation factor 88 signaling pathway in vitro

Transpl Immunol. 2023 Oct 31:101949. doi: 10.1016/j.trim.2023.101949. Online ahead of print.ABSTRACTAsarinin has been found to prolong allograft survival and inhibit post-transplant immune rejection via the Toll-like receptor (TLR) signaling pathway. However, the underlying mechanism is not completely understood. Therefore, elucidating the possible pathophysiological role of asarinin in the TLR signaling pathway is essential. Here, dendritic cells were isolated from Sprague-Dawley® rats and cultured with splenocytes from Wistar rats treated with asarinin, lipopolysaccharide (LPS), and/or dimethyl sulfoxide. mRNA expression of TLR-2, TLR-4, myeloid differentiation factor 88 (MyD88), and nuclear factor kB (NF-kB) was determined using real-time polymerase chain reaction. Interleukin (IL)-6 and IL-12 levels were examined using an enzyme-linked immunosorbent assay. LPS resulted in an increase in the expression of TLR-2 rather than TLR-4 and MyD88. Furthermore, it inhibited the secretion of IL-6 and IL-12. MyD88 can be silenced after lentiviral transduction, and LPS can activate MyD88, whereas asarinin can inhibit this kind of activation. The effect of LPS and asarinin on TLR-4 could only be achieved when MyD88 was not silenced by lentivirus transduction. Therefore, asarinin might suppress TLR-4-mediated activation via the MyD88-dependent pathway. Overall, asarinin has a pre-application effect in inhibiting graft rejection.PMID:37918581 | DOI:10.1016/j.trim.2023.101949
Source: Transplant Immunology - Category: Transplant Surgery Authors: Source Type: research